$ACAN 3.2 +10% Mentioned it. $AYTU keep holding this lotto for the long term. Used to be a $200m company, w/ FDA approval drugs. Big data later this year ( phase 3). Please check Phase 3 companies Valuation. company is trading 50% below cash on hand and will have more $8m cash when need arrives Company products under the spotlight these days:
Drugmakers continue price increases: Aytu BioScience recently bought rights to a spray form of Ambien and then raised the price as much as 843% https://t.co/Dkn6PJQ2SS via @WSJ ;
" the biggest price increase this month -- of more than 700 percent --came from tiny Aytu BioScience Inc., for an obscure sleep drug called Zolpimist"https://t.co/sSM4gwBgBf ; ;
CEO ...
“if we only achieved 5% penetration in each of these markets, that would be approximately $90 to $100M net revenue. A rationally-valued specialty pharma comp would be valued at 3 to 5 times net revenue, so that would approximate a $300M to $500”